Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Vancomycin

Vancomycin

Glycopeptide (IV, PO for C. diff)

MRSALevelsNephrotoxicC diff PO

Indication

MRSA bacteremia/endocarditis β€’ SSTI β€’ meningitis (adjunct) β€’ osteomyelitis β€’ CDI oral

At a glance

INDICATIONS (CORE USE)

Serious MRSA / resistant GP infection IV; **AUC/MIC-guided** dosing; **PO only for C. diff colitis** (not systemic).

ADULT DOSE (STANDARD)

15–20 mg/kg IV q8–12h loading strategies; **AUC 400–600** target many serious infections β€” pharmacy

MAX DOSE

Individualized by AUC β€” not a static 4 g/day rule in all centers

Route

IV (systemic); PO (C. diff only)

PEDIATRIC DOSE

60–80 mg/kg/day divided q6h (max per peds reference); neonatal mg/kg distinct

Do not miss

Must-not-miss safety points

Major warning

- **Nephrotoxicity** β€” worse with aminoglycosides, pip-tazo (debated), contrast, hypotension - **Red man** if rapid infusion β€” extend infusion time - **Ototoxicity** rare IV vs historic reports β€” still monitor risk factors - MRSA MIC creep / heteroresistance β€” consult ID for persistent bacteremia

Indications

USE IF: Serious MRSA / resistant gram-positive infection when susceptible; oral for C. diff. AVOID IF: MSSA infection treatable with beta-lactam (beta-lactam superior for MSSA bacteremia per many guidelines); using PO for systemic infection.

Primary

  • MRSA bacteremia with source control + ID follow-up
  • MRSA pneumonia / SSTI / osteomyelitis when susceptible
  • Clostridioides difficile infection β€” **oral vancomycin** (not IV for colitis)

Secondary

  • Meningitis combination when resistant pneumococcus concern (adjunct per guideline)
  • Enterococcal infection when susceptible and beta-lactam not usable (specialist)

Other

  • Surgical prophylaxis only in severe beta-lactam anaphylaxis protocols (institution-specific)

Dosing

STANDARD (ADULT PO)

IV ~15–20 mg/kg per dose q8–12h (AUC-guided) OR PO 125 mg QID (CDI)

ADULT DOSE

Load then 15–20 mg/kg IV q8–12h OR AUC-based extended infusion per pharmacy **PO**: 125 mg QID (CDI) β€” higher doses in severe per guideline

PEDIATRIC DOSE

Neonatal/pediatric mg/kg schedules differ widely β€” pharmacy mandatory.

MAX DOSE

Dose capped by AUC monitoring and renal function β€” avoid nephrotoxic co-drugs.

Practical Note

Trough-only monitoring being replaced by AUC in many hospitals β€” follow local.

Warnings

Clinical warnings

  • Monitor BP during infusion
  • Neutropenia fever β€” not monotherapy for gram-negatives

Adverse effects

  • AKI
  • phlebitis
  • rash (linear IgA, DRESS rare)

Contraindications

  • Rapid infusion in patient with prior severe infusion reaction when unprepared

Drug interactions

  • Aminoglycosides β€” nephrotoxicity
  • Piperacillin-tazobactam simultaneous Y-site β€” precipitation/nephrotoxicity concern β€” separate lines

Special populations

Pediatrics

60–80 mg/kg/day divided q6h (max per peds reference); neonatal mg/kg distinct

Pregnancy

Use if severe maternal GP infection

Lactation

low oral absorption by infant for maternal IV.

Renal impairment

**Mandatory** adjustment; redose HD per protocol; AUC targets still apply. **CrCl scaffold (FMBM β€” titrate to FDA/SFDA label + institutional pharmacy nomogram):** - **CrCl β‰₯50** β†’ AUC-guided or trough-target maintenance (pharmacy) - **CrCl 10–50** β†’ reduce dose and/or extend interval; **more frequent levels early** - **CrCl <10** / **HD** β†’ per HD protocol + AUC/trough; **high AKI risk** with co-nephrotoxins

Hepatic impairment

No standard IV adjustment.

Elderly

AKI risk; hearing baseline if long course.

Administration

IV infusion β‰₯1 h (often longer); never IM for systemic; PO CDI as tablet/liquid.

Monitoring

  • Monitor: - AUC/MIC (preferred) or trough per protocol β†’ subtherapeutic vs nephrotoxicity β†’ adjust early - Creatinine **β‰₯2–3Γ—/week** inpatient; **more often** with aminoglycoside, pip-tazo, contrast, hypotension - Persistent MRSA bacteremia β†’ metastatic foci, device, and echo per ID (even when levels β€œtherapeutic”)
  • Recheck: - MRSA bacteremia β†’ repeat blood cultures until clearance β†’ persistent positivity β†’ echo + source reassessment - No clinical improvement at 48–72h β†’ reassess diagnosis, resistance, source control, and drug interactions - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)

Overdose / toxicity

Clinical Picture

**Life-threatening (first):** **anaphylaxis**; **AKI**; (rare) **arrhythmia** with electrolyte shifts. **Secondary:** red-man infusion reaction (rate-related).

Immediate Actions

Stop/slow infusion β†’ treat hypersensitivity per severity; fluids; BMP; anaphylaxis β†’ epinephrine if indicated

Antidote

No specific antidote; treat complications (e.g. anaphylaxis β†’ epinephrine per ACLS)

Decontamination

N/A standard IV

Escalation

Anaphylaxis, severe AKI, life-threatening arrhythmia β†’ **ICU**; **severe toxicity with renal failure β†’ hemodialysis clears vancomycin** (and related glycopeptides per agent) β€” redose per level post-HD; ototoxic symptoms β†’ ENT

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**MRSA workhorse IV** β€” **MSSA β†’ prefer nafcillin/cefazolin** for bacteremia when non-anaphylactic. **AUC** is king. PO = **C. diff**, not sepsis.

Clinical pearls

Stewardship: de-escalate to oral linezolid/TMP-SMX/doxycycline when appropriate. Infection control for MRSA. Do not extend IV vanco for non-bacteremic cellulitis beyond guideline duration. *Stewardship (all antimicrobials):* Empiric choice β†’ syndrome severity + **local antibiogram**; shortest effective course.

Stewardship & safety

  • AUC monitoring
  • AKI watch
  • PO β‰  systemic

Pharmacokinetics

Renal elimination; poor oral absorption (except gut lumen effect for CDI); penetrates tissues variably.

Mechanism of action

Inhibits cell wall peptidoglycan β€” time-dependent with AUC/MIC PK/PD for serious infection.

Common brand names

Saudi Arabia

Vancocin, Vancomycin

Global

(placeholder β€” verify local formulary)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • MRSA + surgical prophylaxis pathways vary β€” tie to institutional Ξ²-lactam allergy policy.
  • AUC-guided dosing increasingly standard vs trough-only.
  • Empiric choice β†’ tie to syndrome, severity, and local antibiogram β€” not habit.
  • IV β†’ PO step-down when oral bioavailability and susceptibility allow.
  • Do not use antibiotics for uncomplicated viral illness β€” stewardship.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling

Do not miss

  • Uncomplicated viral URI/bronchitis β†’ antibiotics rarely indicated
  • Narrow or stop when susceptibilities + clinical stability allow
  • Persistent MRSA bacteremia β†’ echo, metastatic foci, MIC consult.
  • Nephrotoxic stacks.
  • AUC monitoring
  • AKI watch
  • PO β‰  systemic